Myriad Genetics (MYGN) Stock Statistics & Valuation Metrics

Myriad Genetics has a market cap or net worth of $360.79M. The enterprise value is $447.89M.

Myriad Genetics has 94,448,210 shares outstanding. The number of shares has decreased by -2.65% in one year.

Myriad Genetics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -10.83%.

The current PE Ratio of Myriad Genetics is ―. Myriad Genetics’s PEG ratio is -0.00867.

In the last 12 months, Myriad Genetics had revenue of 824.50M and earned -365.90M in profits. Earnings per share was -3.96.

In the last 12 months, operating cash flow was 2.40M and capital expenditures -23.20M, giving a free cash flow of -20.80M billion.

Myriad Genetics pays an annual dividend of $1.75, resulting in a dividend yield of ―

Myriad Genetics upcoming earnings date is Jul 30, 2026, TBA (Confirmed).

Myriad Genetics as a current ratio of 2.49, with Debt / Equity ratio of 62.69%

In the past 12 months, Myriad Genetics has paid -29.20M in taxes.

Myriad Genetics EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -45.94.

Myriad Genetics has $124.40M in cash and marketable securities with $211.50M in debt, giving a net cash position of -$87.10M billion.

Gross margin is 69.96%, with operating margin of -8.22%, and net profit margin of -44.38%.

The average price target for Myriad Genetics is $7.20, which is 11.43% higher than the current price. The consensus rating is Hold